Mallinckrodt (NYSE:MNK) received a $23.00 target price from analysts at Barclays in a research report issued to clients and investors on Tuesday, December 12th. The brokerage currently has a “hold” rating on the stock. Barclays’ price target would indicate a potential downside of 1.37% from the stock’s current price.
Other analysts have also recently issued reports about the company. ValuEngine cut Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group decreased their price objective on Mallinckrodt from $70.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, August 25th. BidaskClub raised Mallinckrodt from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Cantor Fitzgerald set a $52.00 price objective on Mallinckrodt and gave the stock a “buy” rating in a research report on Monday, October 2nd. Finally, Canaccord Genuity downgraded Mallinckrodt from a “buy” rating to a “hold” rating and cut their target price for the stock from $77.00 to $40.00 in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $48.14.
Shares of Mallinckrodt (NYSE MNK) traded down $0.25 during midday trading on Tuesday, hitting $23.32. The company had a trading volume of 2,504,489 shares, compared to its average volume of 3,361,508. The firm has a market cap of $2,239.27, a PE ratio of 6.30, a PEG ratio of 0.43 and a beta of 1.30. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. Mallinckrodt has a 1 year low of $19.00 and a 1 year high of $55.32.
In related news, VP Steven J. Romano purchased 2,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was bought at an average price of $21.96 per share, with a total value of $43,920.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mark Trudeau purchased 5,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were bought at an average cost of $22.28 per share, with a total value of $111,400.00. The disclosure for this purchase can be found here. Insiders purchased a total of 30,460 shares of company stock valued at $659,486 over the last ninety days. 0.77% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in MNK. Sentry Investment Management LLC boosted its holdings in Mallinckrodt by 1.6% in the second quarter. Sentry Investment Management LLC now owns 52,676 shares of the company’s stock valued at $2,360,000 after acquiring an additional 817 shares during the last quarter. QS Investors LLC boosted its holdings in Mallinckrodt by 10.8% in the second quarter. QS Investors LLC now owns 9,477 shares of the company’s stock valued at $425,000 after acquiring an additional 923 shares during the last quarter. Accident Compensation Corp boosted its holdings in Mallinckrodt by 2.7% in the second quarter. Accident Compensation Corp now owns 38,390 shares of the company’s stock valued at $1,720,000 after acquiring an additional 1,000 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in Mallinckrodt by 10.5% in the second quarter. Rice Hall James & Associates LLC now owns 10,702 shares of the company’s stock valued at $480,000 after acquiring an additional 1,019 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in Mallinckrodt by 24.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,640 shares of the company’s stock valued at $253,000 after acquiring an additional 1,110 shares during the last quarter. 97.36% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Market News and is the property of of American Market News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/24/mallinckrodt-mnk-pt-set-at-23-00-by-barclays.html.
About Mallinckrodt
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
